In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Medical Services Patients & Visitors Health Library For Medical Professionals Quality About Us PhysicianLink
Text Size:  -   +  |  Print Page  |  Email Page

Breast Cancer



A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER-2 Positive Ductal Carcinoma In Situ (DCIS) Resected by Lumpectomy. 

For additional information please contact Nurdan IIgaz, Clinical Research Coordinator, at 859-260-6406. 
REF# CBG 09-870

A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Follower by Weekly Paclitaxel) to Chemotherapy plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer.

For additional information please contact Nurdan IIgaz, Clinical Research Coordinator, at 859-260-6406.
REF# CBH 11-953

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy In Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. 

For additional information please contact Heather Tudor, Clinical Research Coordinator, at 859-260-3196.
REF# CBH 11-979

A Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of High Dose Vitamin D in Premenopausal Women at High-Risk for Breast Cancer, Phase IIB.

For additional information please contact Heather Tudor, Clinical Research Coordinator, at 859-260-3196.
REF# CBH 12-1023

A Phase III Clinical Trial Comparing the Cominbation of Docetaxel Plus Cyclophospamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer.

For additional information please contact Nurdan IIgaz, Clinical Research Coordinator, at 859-260-6406.
REF# CBH 12-1033

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/NEU Negative Breast Cancer.

For additional information please contact Heather Tudor, Clinical Research Coordinator, at 859-260-3196.
REF# CBH-13-1084

A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2-Directed Regimens in the Metastatic Setting (NALA).

 

    For additional information please contact Heather Tudor, Clinical Research Coordinator, at 859-260-3196. 
   REF# BHL-13-1096

 

Phase II Study of Neoadjuvant Letrozole for Post-Menopausal Women with Estrogen Receptor Positive Ductal Carcinoma In Situ.

 

    For additional information please contact Nurdan Ilgaz, Clinical Research Coordinator, at 859-260-6406. 
   REF# BHL-13-110
1